Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- PMID: 31492944
- DOI: 10.1038/s41573-019-0038-z
Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Abstract
Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively, but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently, there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review, we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.
Similar articles
-
γδT cells, a key subset of T cell for cancer immunotherapy.Front Immunol. 2025 Mar 28;16:1562188. doi: 10.3389/fimmu.2025.1562188. eCollection 2025. Front Immunol. 2025. PMID: 40226616 Free PMC article. Review.
-
Function of γδ T cells in tumor immunology and their application to cancer therapy.Exp Mol Med. 2021 Mar;53(3):318-327. doi: 10.1038/s12276-021-00576-0. Epub 2021 Mar 12. Exp Mol Med. 2021. PMID: 33707742 Free PMC article. Review.
-
Harnessing the power of Vδ2 cells in cancer immunotherapy.Clin Exp Immunol. 2015 Apr;180(1):1-10. doi: 10.1111/cei.12564. Clin Exp Immunol. 2015. PMID: 25469879 Free PMC article. Review.
-
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.Int J Mol Sci. 2021 Aug 18;22(16):8910. doi: 10.3390/ijms22168910. Int J Mol Sci. 2021. PMID: 34445615 Free PMC article. Review.
-
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy.Front Immunol. 2024 Mar 21;15:1360237. doi: 10.3389/fimmu.2024.1360237. eCollection 2024. Front Immunol. 2024. PMID: 38576617 Free PMC article. Review.
Cited by
-
Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.Vaccines (Basel). 2022 Sep 7;10(9):1493. doi: 10.3390/vaccines10091493. Vaccines (Basel). 2022. PMID: 36146572 Free PMC article. Review.
-
The landscape of bispecific T cell engager in cancer treatment.Biomark Res. 2021 May 26;9(1):38. doi: 10.1186/s40364-021-00294-9. Biomark Res. 2021. PMID: 34039409 Free PMC article. Review.
-
Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines.Biomacromolecules. 2023 Mar 13;24(3):1164-1172. doi: 10.1021/acs.biomac.2c01207. Epub 2023 Feb 6. Biomacromolecules. 2023. PMID: 36745712 Free PMC article.
-
Murine CXCR3+CXCR6+γδT Cells Reside in the Liver and Provide Protection Against HBV Infection.Front Immunol. 2022 Jan 21;12:757379. doi: 10.3389/fimmu.2021.757379. eCollection 2021. Front Immunol. 2022. PMID: 35126348 Free PMC article.
-
The association of γδT lymphocytes with cystic leukomalacia in premature infants.Front Neurol. 2022 Dec 2;13:1043142. doi: 10.3389/fneur.2022.1043142. eCollection 2022. Front Neurol. 2022. PMID: 36530609 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical